Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

Among hospitalized adults with type 2 diabetes from 2015 to 2020, 3.7% were prescribed an SGLT2 inhibitor. Only 0.2% of hospitalized adults with type 2 diabetes were prescribed a GLP-1 receptor ...

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

Taiwan: A recent cohort study has highlighted the potential benefits of combining glucagon-like peptide-1 receptor agonists ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

“GLP-1 receptor agonist use was not associated with an increased risk of suicidal ideation, self-harm, or suicide” compared against two other classes of diabetes medications, wrote the research team ...

Opens in a new tab or window New GLP-1 receptor agonist users did not have an excess risk for suicidality compared with DPP-4 inhibitor and SGLT2 inhibitor users. They also didn't have an excess ...

There was no difference for depression risk between new GLP-1 receptor agonist users and SGLT2 inhibitor users. Duration of GLP-1 receptor agonist use and depression risk were inversely associated.

The second group included individuals who started and continued either a GLP-1 receptor agonist or SGLT-2 inhibitor for the first time between January 1, 2013, and December 31, 2020. The primary ...